 Despite extensive research, there are no licensed vaccines against common alpha herpes viruses such as HSV1 and 2 or EBV, which reside in the regional sensory ganglia in a latent state. A purified subunit vaccine and recombinant fusion protein have been designed for immunotherapy against these viruses. An EBV-peptid vaccine consisting of 15 carefully selected epitopes from 12 virus-coded proteins bound to synthetic microparticle carriers has shown satisfactory protective effects in a rabbit model, based on criteria such as antibody formation and presence of LMP1 antigen and viral DNA in peripheral white blood cells. This article was authored by Julius Rajani, Fierinck Bernati, Kalman Senth, and others.